InvestorsHub Logo
Followers 271
Posts 53154
Boards Moderated 3
Alias Born 08/16/2008

Re: None

Wednesday, 09/27/2023 11:10:47 AM

Wednesday, September 27, 2023 11:10:47 AM

Post# of 300
SLNO was one of the two BIG runners yesterday.

It closed up 505%, from $4.43 to $26.80!

It made all four of our five positive scans: Most Active #2, highest % Gainer #1, Highest Dollar Increase #1 and 52 Week High #1

Wow, that's impressive! So what was behind this stratospheric jump?

Soleno Therapeutics' Study Outcome Bolsters Confidence In PWS Treatment

BENZINGA 3:18 PM ET Sep-26-2023

Earlier on Tuesday, Soleno Therapeutics Inc (NASDAQ:SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS).

Cantor Fitzgerald raised the price target on Soleno Therapeutics from $19 to $35, with an Overweight rating.

The analysts Kristen Kluska, Richard Miller, and Jason Bouvier note that the trial outcome is as good as could have been expected.

The analysts say the data suggests promising signals regarding the treatment's durability.

The analyst suggests that the Prader-Willi Syndrome (PWS) market could hold significant appeal for Soleno Therapeutics. PWS is a rare condition, but patients typically receive early diagnoses.

Additionally, considerable awareness of this drug exists within the patient and family communities, indicating a favorable environment for a potential first-to-market opportunity.

Cantor also writes that throughout the trial, the efficacy curves for the placebo and the drug consistently diverged early, never crossed paths, and exhibited increasing separation over time.

Cantor writes that the outcome opens the door to a potential New Drug Application filing, which could support a potential approval, marking the first FDA-approved drug for PWS.

The analysts still believe the Soleno Therapeutics stock remains undervalued as it is trading at roughly 1x 2029E revenue, and they model 2035E revenues of ~$1 billion.

Price Action: SLNO shares are up 507.8% at $26.75 on the last check Tuesday.

Wonderful- a real play!! Last four we looked at were essentially Pump& Dumps. Nice to see a real one!

This morning it is trailing off, but not too badly, relatively speaking. At writing SLNO is

SOLENO THERAPEUTICS INC $22.80 -4.00 (-14.93%)

As of Sep-27-202311:00:01 AM ET

Soleno has substantial 'tute ownership. And why not- it has a promising Phase Three candidate.

Institutional ownership
49.8%
Institutional mutual fund ownership
1.2%
Mutual fund ownership
0.0%
Insider ownership
2.9%
Other
46.0%

Hooray!! It took five days to identify a legitimate runner.

MG
for the $Stock*Shop*Charts*News*Option$ board
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SLNO News